NO20015931L - Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin - Google Patents

Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin

Info

Publication number
NO20015931L
NO20015931L NO20015931A NO20015931A NO20015931L NO 20015931 L NO20015931 L NO 20015931L NO 20015931 A NO20015931 A NO 20015931A NO 20015931 A NO20015931 A NO 20015931A NO 20015931 L NO20015931 L NO 20015931L
Authority
NO
Norway
Prior art keywords
morphine
methods
pharmaceutically acceptable
acceptable salt
pharmaceutical formulations
Prior art date
Application number
NO20015931A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015931D0 (no
Inventor
Charanjit R Behl
Raja G Achari
Jorge C Demeireles
Ramneik Dua
Vincent D Romeo
Anthony P Sileno
Original Assignee
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co
Publication of NO20015931D0 publication Critical patent/NO20015931D0/no
Publication of NO20015931L publication Critical patent/NO20015931L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20015931A 1999-06-16 2001-12-04 Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin NO20015931L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33453799A 1999-06-16 1999-06-16
PCT/US2000/014157 WO2000076506A1 (en) 1999-06-16 2000-05-23 Pharmaceutical formulations and methods comprising intranasal morphine

Publications (2)

Publication Number Publication Date
NO20015931D0 NO20015931D0 (no) 2001-12-04
NO20015931L true NO20015931L (no) 2002-02-08

Family

ID=23307687

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015931A NO20015931L (no) 1999-06-16 2001-12-04 Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin

Country Status (30)

Country Link
US (1) US6677346B1 (de)
EP (2) EP1183027A4 (de)
JP (1) JP2003501467A (de)
KR (1) KR20020016831A (de)
AU (1) AU774175B2 (de)
BG (1) BG106221A (de)
BR (1) BR0012082A (de)
CA (1) CA2374877C (de)
CZ (1) CZ20014399A3 (de)
DE (1) DE10084709T1 (de)
DK (1) DK200101859A (de)
EE (1) EE200100677A (de)
ES (1) ES2197792B1 (de)
FI (1) FI20012462A (de)
GB (1) GB2367005A (de)
HR (1) HRP20010926A2 (de)
HU (1) HUP0201856A3 (de)
IS (1) IS6202A (de)
LT (1) LT4976B (de)
LU (1) LU90859B1 (de)
LV (1) LV12859B (de)
MX (1) MXPA01012879A (de)
NO (1) NO20015931L (de)
NZ (1) NZ515783A (de)
PL (1) PL352556A1 (de)
SE (1) SE0104203L (de)
SI (1) SI20850A (de)
SK (1) SK18172001A3 (de)
TR (1) TR200103613T2 (de)
WO (1) WO2000076506A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
WO2002024116A1 (en) * 2000-09-20 2002-03-28 Shahinian, Lee, Jr. Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US20030003113A1 (en) * 2001-06-29 2003-01-02 Lewandowski Leon J. Individualized addiction cessation therapy
GB0210264D0 (en) * 2002-05-03 2002-06-12 Arakis Ltd The treatment of pain and migraine headache
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
NZ555501A (en) 2004-11-24 2010-01-29 Medpointe Healthcare Inc Compositions comprising azelastine and methods of use thereof
US9415034B2 (en) * 2005-01-05 2016-08-16 National Defense Medical Center Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B)
ES2277743B2 (es) * 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
BRPI0720434A2 (pt) * 2006-12-22 2014-01-07 Sigma Tau Ind Farmaceuti Gel útil para liberação de fármacos oftálmicos
GB2477545B (en) * 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
MX354249B (es) 2011-05-13 2018-02-20 Euro Celtique Sa Formas de dosificación farmacéuticas intranasales que comprenden naloxona.
EP2877178A1 (de) 2012-07-26 2015-06-03 Wockhardt Limited Pharmazeutische zusammensetzung mit diamorphin zur intranasalen verabreichung
EP3082817A4 (de) * 2013-12-18 2017-06-21 Aegis Therapeutics, LLC Zusammensetzungen zur arzneimittelverabreichung
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3242676B1 (de) 2015-01-07 2023-10-04 Tonix Pharmaceuticals Holding Corp. Magnesiumhaltige oxytocinformulierungen und verfahren zur verwendung
CA3041308A1 (en) * 2016-10-21 2018-04-26 Somniferum Labs LLC Method, system and apparatus for controlled delivery of opioid and other medications
WO2019076997A1 (en) * 2017-10-20 2019-04-25 Chiesi Farmaceutici S.P.A. PHARMACEUTICAL FORMULATIONS COMPRISING AN OPIOID RECEPTOR AGONIST AS ACTIVE SUBSTANCES, METHODS OF MAKING THEM AND THERAPEUTIC USES THEREOF
EA202091615A1 (ru) 2018-12-21 2021-03-05 Аегис Терапьютикс, Ллс Интраназальные составы на основе эпинефрина и способы лечения заболевания
CN115804754A (zh) * 2022-12-16 2023-03-17 广州新济药业科技有限公司 吗啡鼻喷剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4464376A (en) 1982-07-22 1984-08-07 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
EP0689438B1 (de) * 1993-03-26 2003-06-04 Franciscus Wilhelmus Henricus Maria Merkus Pharmazeutische zusammensetzungen zur intranasalen verabreichung von apomorphin
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
JP2001501212A (ja) * 1996-09-27 2001-01-30 ナステック ファーマシューティカル カンパニー インク 睡眠促進用鼻腔内調製物及び同物を用いる方法

Also Published As

Publication number Publication date
FI20012462A (fi) 2002-01-16
ES2197792A1 (es) 2004-01-01
BG106221A (en) 2002-08-30
EP1183027A1 (de) 2002-03-06
GB0128383D0 (en) 2002-01-16
EP1183027A4 (de) 2003-02-05
LV12859B (en) 2002-12-20
AU774175B2 (en) 2004-06-17
HRP20010926A2 (en) 2003-04-30
CA2374877C (en) 2004-04-13
ES2197792B1 (es) 2005-05-01
CA2374877A1 (en) 2000-12-21
DE10084709T1 (de) 2002-09-26
GB2367005A (en) 2002-03-27
WO2000076506A1 (en) 2000-12-21
LU90859B1 (en) 2002-01-24
MXPA01012879A (es) 2003-06-24
HUP0201856A3 (en) 2004-12-28
EE200100677A (et) 2003-02-17
US6677346B1 (en) 2004-01-13
KR20020016831A (ko) 2002-03-06
JP2003501467A (ja) 2003-01-14
CZ20014399A3 (cs) 2002-06-12
SK18172001A3 (sk) 2002-07-02
IS6202A (is) 2001-12-14
LT4976B (lt) 2002-12-30
HUP0201856A1 (en) 2002-09-28
LT2001119A (en) 2002-07-25
TR200103613T2 (tr) 2004-08-23
SE0104203D0 (sv) 2001-12-14
DK200101859A (da) 2001-12-12
BR0012082A (pt) 2002-05-07
NZ515783A (en) 2004-05-28
PL352556A1 (en) 2003-08-25
NO20015931D0 (no) 2001-12-04
EP1419774A1 (de) 2004-05-19
AU5156100A (en) 2001-01-02
SI20850A (sl) 2002-10-31
SE0104203L (sv) 2001-12-14

Similar Documents

Publication Publication Date Title
NO20015931L (no) Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
NO20040968L (no) Opioidagonistpreparater med frigjorbar og sekvestrert antagonist
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
EP1033998A4 (de) Methode zur unterdrückung von beta-amyloid-verwandten veränderungen in alzheimer
ATE247461T1 (de) Formulierung zur intranasalen verabreichung
MX344036B (es) Composiciones que comprenden azelastina y metodos de uso de la misma.
AU3846901A (en) Oral, nasal and pulmonary dosage formualtions of copolymer 1
MXPA01012882A (es) Composiciones y metodos que comprenden gluconato de morfina.
TW200633694A (en) Composition and method for treating asthma
DK1039900T3 (da) Farmaceutisk præparat indeholdende sibutramin og orlistat
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
TW200700075A (en) Roflumilast and integrin inhibitor combination and method of treatment
GB2426707A (en) A stable parental formulation of levomepromazine and a method for stabilizing said formulation
BR0011880A (pt) Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
SE0002354D0 (sv) New formulation
WO2003066806A3 (en) Therapeutic use of aziridino compounds
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"
AU2001295839A1 (en) Use of agents active against candida in the treatment of disorders of the oral and intestinal mucosa
EE200300555A (et) Morfiini sisaldav farmatseutiline preparaat ninasiseseks manustamiseks ning meetod valuvaigistava või tuimastava reaktsiooni esilekutsumiseks imetajal
WO2001035946A3 (en) Intranasal administration of raloxifene and tamoxifen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application